Entry inhibitors in the treatment of HIV-1 infection.
暂无分享,去创建一个
[1] T. Matthews,et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus , 2007, Proceedings of the National Academy of Sciences.
[2] Stephen C. Peiper,et al. Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions , 1999, Journal of Virology.
[3] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[4] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.
[5] Dominique Schols,et al. Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.
[6] Zheng Yang,et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Broder,et al. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Lachowicz,et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonis , 2004, Journal of medicinal chemistry.
[9] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[10] R. Koup,et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.
[11] B. Olde,et al. Coevolution of RANTES Sensitivity and Mode of CCR5 Receptor Use by Human Immunodeficiency Virus Type 1 of the R5 Phenotype , 2004, Journal of Virology.
[12] D. Kuritzkes,et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. , 2004, The Journal of infectious diseases.
[13] Jay Rappaport,et al. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes , 1997, The Lancet.
[14] G. Ciaramella,et al. Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry , 2006, Journal of Virology.
[15] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[16] A. Otaka,et al. Structure-activity relationships of an anti-HIV peptide, T22. , 1994, Biochemical and biophysical research communications.
[17] M. Lederman,et al. Chemokine Analogues Show Suitable Stability for Development as Microbicides , 2008, Journal of acquired immune deficiency syndromes.
[18] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[19] Shibo Jiang,et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains , 2008, Proceedings of the National Academy of Sciences.
[20] C. Mackay,et al. Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.
[21] Reed J. Harris,et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.
[22] Steven M. Wolinsky,et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.
[23] Robert Blumenthal,et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Gorlin,et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.
[25] J J Goedert,et al. Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.
[26] Q. Sattentau,et al. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells , 1992, Journal of virology.
[27] Don C. Wiley,et al. Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.
[28] Bernhard Moser,et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.
[29] N. Graham,et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.
[30] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[31] R. Doms,et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. , 2001, AIDS research and human retroviruses.
[32] J. Sodroski,et al. Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State , 2009, PLoS pathogens.
[33] H. Schuitemaker,et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.
[34] D. Pillay,et al. Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 , 2005, Antimicrobial Agents and Chemotherapy.
[35] Martin S. Hirsch,et al. Strong in Vitro Synergy Between the Fusion Inhibitor T‐20 and the CXCR4 Blocker AMD‐3100 , 2000, Journal of acquired immune deficiency syndromes.
[36] R. Doms,et al. HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide , 2009, Journal of Virology.
[37] J. Lifson,et al. Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.
[38] John P. Moore,et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. , 2007, Virology.
[39] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[40] Kenneth A. Taylor,et al. Cryoelectron Tomography of HIV-1 Envelope Spikes: Further Evidence for Tripod-Like Legs , 2008, PLoS pathogens.
[41] John P. Moore,et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.
[42] Hans Wolf,et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.
[43] J. Albert,et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. , 2005, The Journal of general virology.
[44] E. Hunter,et al. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity , 1992, Journal of virology.
[45] J. Sodroski,et al. Stoichiometry of Envelope Glycoprotein Trimers in the Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.
[46] William C. Olson,et al. Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes , 2001, Journal of Virology.
[47] J. Kappes,et al. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.
[48] H. Schuitemaker,et al. Sensitivity of Primary R5 HIV-1 to Inhibition by Rantes Correlates with Sensitivity to Small-Molecule R5 Inhibitors , 2005, Antiviral Therapy.
[49] Mike Youle,et al. Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir , 2006, Journal of Virology.
[50] J. Mascola,et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel , 2000, AIDS.
[51] B. Margolin,et al. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability , 1993, Journal of virology.
[52] Masahiko Kuroda,et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.
[53] A Muñoz,et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.
[54] T. Oas,et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[55] Carlos Toro,et al. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure , 2004, Journal of medical virology.
[56] A. Trkola,et al. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.
[57] H. Schuitemaker,et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. , 2003, The Journal of infectious diseases.
[58] Emmanuel G. Cormier,et al. The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor , 2002, Journal of Virology.
[59] C. Broder,et al. Mutagenesis of CXCR4 Identifies Important Domains for Human Immunodeficiency Virus Type 1 X4 Isolate Envelope-Mediated Membrane Fusion and Virus Entry and Reveals Cryptic Coreceptor Activity for R5 Isolates , 1999, Journal of Virology.
[60] J. Kappes,et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.
[61] T. Chun,et al. Biochemical and Biological Characterization of a Dodecameric CD4-Ig Fusion Protein , 2002, The Journal of Biological Chemistry.
[62] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[63] R. Redfield,et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.
[64] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[65] Peter D. Kwong,et al. Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 , 2007, Science.
[66] M. Hughes,et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. , 2007, The Journal of infectious diseases.
[67] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[68] B. Wood,et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist , 2005, Transfusion.
[69] Q. Sattentau,et al. Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans , 1998, Journal of Virology.
[70] M. Polis,et al. Drug interactions in patients infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] J. Albert,et al. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection , 1994, Journal of clinical microbiology.
[72] T. Matthews,et al. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.
[73] M. Baba,et al. Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652 , 2006, Antimicrobial Agents and Chemotherapy.
[74] E. Fenyö,et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.
[75] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[76] John P. Moore,et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249 , 2008, Proceedings of the National Academy of Sciences.
[77] M. Locati,et al. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. , 1997, Virology.
[78] J. Margolick,et al. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study , 2000, AIDS.
[79] J. Sodroski,et al. Identification of Conserved and Variable Structures in the Human Immunodeficiency Virus gp120 Glycoprotein of Importance for CXCR4 Binding , 2002, Journal of Virology.
[80] J. Howe,et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. , 2008, Virology.
[81] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[82] N. Graham,et al. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy , 2007, AIDS.
[83] J. Park,et al. Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects , 2007, Antimicrobial Agents and Chemotherapy.
[84] R. Doms,et al. Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins , 2003, Journal of Virology.
[85] Shibo Jiang,et al. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors , 2009, AIDS.
[86] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[87] Douglas S Kwon,et al. DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.
[88] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[89] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[90] P. Rose,et al. Adaptive Mutations in the V3 Loop of gp120 Enhance Fusogenicity of Human Immunodeficiency Virus Type 1 and Enable Use of a CCR5 Coreceptor That Lacks the Amino-Terminal Sulfated Region , 2001, Journal of Virology.
[91] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[92] Kenneth A. Taylor,et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[93] T. Oas,et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[94] Kouji Matsushima,et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.
[95] Anthony S. Fauci,et al. AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.
[96] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[97] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[98] Jun Zhang,et al. CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor , 2007, Molecular Pharmacology.
[99] Cassandra B. Jabara,et al. Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization , 2005, Journal of Virology.
[100] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[101] J. Word,et al. Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope , 2008, Antimicrobial Agents and Chemotherapy.
[102] J. Sodroski,et al. Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120 , 2000, Journal of Virology.
[103] J. Sodroski,et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. , 2006, Biochemistry.
[104] Wei Huang,et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. , 2007, The Journal of infectious diseases.
[105] Yuetsu Tanaka,et al. The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100 , 2009, Antimicrobial Agents and Chemotherapy.
[106] D. Ho,et al. In Vivo Distribution of the Human Immunodeficiency Virus/Simian Immunodeficiency Virus Coreceptors: CXCR4, CCR3, and CCR5 , 1998, Journal of Virology.
[107] D. Ho,et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[108] R. Lal,et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. , 1998, Virology.
[109] G. Melikyan,et al. HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes , 2009, Cell.
[110] Shibo Jiang,et al. HIV-1 inhibition by a peptide , 1993, Nature.
[111] Y. Cao,et al. HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.
[112] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.
[113] Pascal Poignard,et al. Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.
[114] K. Kabeya,et al. Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140) , 2007, Antimicrobial Agents and Chemotherapy.
[115] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[116] T. Schwartz,et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.
[117] Joel E Gallant,et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy , 2003, AIDS.
[118] H. Guy,et al. Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.
[119] R. Davey,et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults , 2005, AIDS.
[120] Michael S. Kay,et al. Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.
[121] Marc Parmentier,et al. The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.
[122] J. Sodroski,et al. Localized Changes in the gp120 Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155 , 2004, Journal of Virology.
[123] H. Schuitemaker,et al. Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.
[124] D. Richman,et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine , 2003, AIDS.
[125] James E. Robinson,et al. Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events , 2006, Journal of Virology.
[126] R. Doms,et al. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. , 2009, Virology.
[127] Michael Greenberg,et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.
[128] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[129] J. Goudsmit,et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.
[130] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[131] M. Baba,et al. T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure , 1999, Journal of Virology.
[132] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[133] X Zhang,et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.
[134] G. D. Miralles,et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. , 2005, The Journal of infectious diseases.
[135] A. Lazzarin,et al. Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations , 2008, Journal of medical virology.
[136] T L Hoffman,et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[137] M. Hirsch,et al. Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.
[138] S. Yerly,et al. Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.
[139] P. Volberding,et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. , 2002, AIDS research and human retroviruses.
[140] A. Trkola,et al. Estimating the Stoichiometry of Human Immunodeficiency Virus Entry , 2008, Journal of Virology.
[141] M. Lederman,et al. Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 , 2004, Science.
[142] Y. Iwasaki,et al. Efficient inhibition of SDF‐1α‐mediated chemotaxis and HIV‐1 infection by novel CXCR4 antagonists , 2009, Cancer science.
[143] M. Goldsmith,et al. Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.
[144] Marc Parmentier,et al. Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.
[145] A. Trkola,et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[146] John P. Moore,et al. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 , 2009, Proceedings of the National Academy of Sciences.
[147] D. Missé,et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes , 2003, Nature Biotechnology.
[148] H. Sheppard,et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression , 1997, Nature Medicine.
[149] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[150] David A. Price,et al. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.
[151] J. Sodroski,et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[152] Steven G. Deeks,et al. Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility ofHuman Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors , 2007, Journal of Virology.
[153] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.